December 10th 2018
Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.
November 30th 2018
Genesis Healthcare Partners, the region’s largest independent urology practice, is challenged by regulatory changes and the dominance of the regional managed care market, which has huge control of patient flow and payment structures.
November 28th 2018
The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.
November 12th 2018
Investigators are assessing whether Oraxol, an oral formulation of paclitaxel, will be safer and more efficacious than the widely used chemotherapy drug administered by traditional intravenous infusion.
October 8th 2018
Investigators are evaluating whether eryaspase (Graspa), an L-asparaginase-based therapy that triggers tumor cell death, can extend survival for patients with pancreatic cancer.
October 2nd 2018
The FDA has granted the PARP inhibitor rucaparib a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.
October 2nd 2018
Investigators are hopeful that M7824, a bifunctional fusion protein that inhibits the PD-L1 and TGF-β pathways, will improve immune system responses across tumor types.
September 19th 2018
Virginia Urology, a practice with specialists in surgery, radiation, and oncology, has grown steadily over 75 years by remaining patient focused. Centered in Richmond, Virginia Urology has always prioritized quality care.
August 30th 2018
In recent years, tyrosine kinase inhibitors that specifically target RET have entered the pipeline. Although none have yet received FDA approval, the promise of these agents has spurred interest in diagnostic assays.
August 22nd 2018
Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.